Pulmonary Fibrosis (Idiopathic Pulmonary Fibrosis)
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Idiopathic pulmonary fibrosis is a chronic lung disease in which normal flexible lung tissue is progressively replaced by excessive fibrous scar tissue. West Highland White Terriers are particularly predisposed, and the strong breed association suggests a genetic contribution, although the exact cause and mode of inheritance are not fully defined.
Fibrotic lung tissue is stiff and cannot expand or exchange oxygen as efficiently as healthy lung. The earliest sign is often reduced exercise tolerance. A dog that previously walked comfortably may begin slowing down, stopping more often or breathing heavily after modest activity. As disease progresses, the resting respiratory rate increases and the dog may develop a dry cough, laboured breathing or episodes of fainting caused by inadequate oxygen delivery.
Veterinarians often hear characteristic crackling sounds on chest auscultation.
Pulmonary hypertension can develop because scarred lungs increase resistance to blood flow through the pulmonary circulation. This further reduces exercise tolerance and can complicate treatment.
The disease is slowly progressive and there is no therapy that removes established fibrosis. Prognosis varies, but respiratory capacity tends to decline over time. The management goal is therefore to maximise oxygen exchange, control associated airway or vascular problems and preserve comfort as long as possible.
Fibrotic lung tissue becomes stiff and less able to transfer oxygen efficiently into the bloodstream. Dogs therefore compensate by breathing faster and working harder, especially during activity. Exercise intolerance may be subtle initially, but progression can lead to persistent rapid breathing, coughing, fainting or bluish mucous membranes when oxygen levels become severely reduced.
Annual auscultation is valuable because fine inspiratory crackles may be heard before owners recognise severe respiratory limitation. Blue-grey gums, marked respiratory distress and collapse represent an acute loss of respiratory reserve. Progressive exercise intolerance should not be attributed automatically to age or arthritis in a predisposed breed.
Screening & Early Detection
Idiopathic pulmonary fibrosis cannot currently be predicted in a healthy West Highland White Terrier using a DNA test or simple blood screen. Early detection relies on recognising changes in breathing and on careful veterinary examination, particularly from middle age onward.
Owners can also monitor resting or sleeping respiratory rate at home. A persistent increase from the dog’s usual baseline, reduced walking tolerance or new cough should prompt assessment.
Chest radiographs are a common first imaging test but may not distinguish fibrosis from every other interstitial lung disease. High-resolution CT is more sensitive and can show patterns strongly supportive of pulmonary fibrosis. Echocardiography is useful when pulmonary hypertension is suspected, and blood tests or infectious-disease testing help exclude alternative causes.
Because the disease can advance gradually, serial examinations and respiratory-rate records are useful. Screening is most effective when it identifies a consistent trend in respiratory function early enough to investigate before the dog is struggling at rest.
Chest radiographs can show an interstitial lung pattern, but high-resolution CT provides much greater detail and helps distinguish fibrosis from other chronic lung diseases. Blood tests, infection testing and cardiac assessment may be used to rule out alternative causes. Definitive diagnosis historically required lung biopsy, although advanced imaging and breed-typical presentation can sometimes provide strong clinical confidence without invasive sampling.
Treatment & Management
Established pulmonary fibrosis cannot currently be reversed, so treatment focuses on respiratory comfort, oxygenation and management of complications. Management is therefore palliative and aimed at improving breathing comfort, controlling complications and reducing unnecessary respiratory stress.
Bronchodilator medication may help dogs that have concurrent airway narrowing, while anti-inflammatory drugs are sometimes used in selected cases. Their benefit for the fibrotic process itself is limited. When pulmonary hypertension develops, medications that reduce pulmonary vascular pressure can improve exercise tolerance and quality of life in some dogs.
Supplemental oxygen is useful during episodes of significant hypoxaemia or respiratory crisis. At home, exercise should be gentle and self-limited. Heat, humidity, obesity and intense exertion increase respiratory demand and should be avoided. A harness is preferable to anything that restricts the neck or airway.
Cough suppressants or other symptomatic medications may be used when appropriate, but cough should first be evaluated to ensure it is not signalling infection, heart disease or another treatable problem. Vaccination and prompt management of respiratory infections are important because already compromised lungs have less reserve.
Monitoring includes resting respiratory rate, oxygenation when available, exercise tolerance and signs of pulmonary hypertension. As disease advances, owners may need to shorten walks and prioritise calm activities. The long-term outlook is guarded, and quality-of-life review becomes increasingly important when the dog can no longer rest or move without breathlessness despite therapy.
